Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
476 stopped studies mapped to Malignant Ovarian Neoplasm and descendants · 86% state a reason
Over the 476 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02117817 | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian… | Phase 1 | withdrawn | Apr 21, 2014 | Rutgers, The State University of New Jersey | Research cancelled | Other (stated, no rule matched) |
| NCT04941378 | OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian… | Phase 1 | withdrawn | Jun 28, 2021 | Abramson Cancer Center at Penn Medicine | Due to sponsor request | Other (stated, no rule matched) |
| NCT03382574 | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing… | Early Phase 1 | terminated | Dec 26, 2017 | National Cancer Institute (NCI) | it was decided that due to lack of accrual on the trial, and low potential for accruing over the… | Enrollment / accrual |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian,…(ORION-01) | Phase 1 / Phase 2 | terminated | Apr 4, 2017 | National Cancer Centre, Singapore | The study had poor efficacy. | Efficacy / futility |
| NCT02900560 | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian… | Phase 2 | terminated | Sep 14, 2016 | Translational Research in Oncology | not stated | Not stated |
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | Phase 2 / Phase 3 | withdrawn | Mar 12, 2021 | Menoufia University | Poor accrual | Enrollment / accrual |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant… | Phase 1 | terminated | Apr 23, 2019 | Vanderbilt-Ingram Cancer Center | Change in participant landscape and other treatment availability | Other (stated, no rule matched) |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | Phase 1 | withdrawn | Nov 2, 2020 | HonorHealth Research Institute | Salarius discontinued support | Other (stated, no rule matched) |
| NCT03690739 | Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian… | Phase 3 | terminated | Oct 1, 2018 | AGO Research GmbH | Insufficient Recruitment | Enrollment / accrual |
| NCT01881451 | Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian… | — | terminated | Jun 19, 2013 | British Columbia Cancer Agency | Due to slow accrual and access to the study drug. | Enrollment / accrual |
| NCT01485874 | Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer | Phase 1 | terminated | Dec 6, 2011 | Hoosier Cancer Research Network | Funding withdrawn due to drug unavailability | Funding |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT04367467 | Effect of PARP Inhibitors on Glomerular Filtration Rate | — | terminated | Apr 29, 2020 | University of Pennsylvania | Due to constraints of COVID19, we were unable to recruit on-site for this study. | COVID-19 / pandemic |
| NCT03029611 | IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV… | Phase 2 | terminated | Jan 24, 2017 | University of Washington | Terminated due to lack of funding | Funding |
| NCT03905902 | DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary…(VITALIA) | Phase 3 | withdrawn | Apr 8, 2019 | SOTIO a.s. | Company decision | Sponsor / business decision |
| NCT01018563 | An Open Label Extension Study of the Efficacy of MORAb-003 | Phase 2 | terminated | Nov 23, 2009 | Morphotek | Study was terminated by sponsor due to futile results in NCT00849667 study. | Other (stated, no rule matched) |
| NCT01312389 | A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian,… | Phase 1 / Phase 2 | terminated | Mar 10, 2011 | Abramson Cancer Center at Penn Medicine | Did not meet criteria laid out in Phase 1 to continue to Phase 2 | Other (stated, no rule matched) |
| NCT03342417 | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | Phase 2 | terminated | Nov 17, 2017 | ExcellaBio LLC | Slow patient accrual | Enrollment / accrual |
| NCT01035658 | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary… | Phase 1 / Phase 2 | terminated | Dec 21, 2009 | SCRI Development Innovations, LLC | Based on analyses in Phase I, the study did not advance to Phase II. | Other (stated, no rule matched) |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer… | Phase 1 / Phase 2 | withdrawn | Aug 16, 2018 | Immune System Key Ltd | Patients were screened but not enrolled | Enrollment / accrual |
| NCT01170650 | Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination…(PROCEED) | Phase 3 | terminated | Jul 27, 2010 | Endocyte | DSMB decision | Other (stated, no rule matched) |
| NCT03607955 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial… | Phase 1 | withdrawn | Jul 31, 2018 | Washington University School of Medicine | Trial may move forward as an NCI-sponsored trial and not an investigator initiated trial. | Investigator |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian… | Phase 1 | terminated | Aug 1, 2018 | MaxCyte, Inc. | Sponsor shift in focus | Other (stated, no rule matched) |
| NCT03933761 | Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or…(PRECISE) | Phase 2 | withdrawn | May 1, 2019 | Australia New Zealand Gynaecological Oncology Group | No eligible patient identified after 18 evaluable patients underwent pre-screening over a 2 year… | Other (stated, no rule matched) |
| NCT03806049 | Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard… | Phase 3 | withdrawn | Jan 16, 2019 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Lack of financial support | Funding |
| NCT00582205 | Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and… | Phase 2 | terminated | Dec 28, 2007 | University of Oklahoma | Study completed per investigator. | Investigator |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic… | Phase 1 | withdrawn | Aug 4, 2020 | Pamela Munster | Funding | Funding |
| NCT02055690 | PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent…(PAZOFOS) | Phase 1 / Phase 2 | terminated | Feb 5, 2014 | The Christie NHS Foundation Trust | Safety | Safety / toxicity |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03029585 | Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer | Phase 2 | terminated | Jan 24, 2017 | NanOlogy, LLC | Business reasons | Sponsor / business decision |
| NCT04239014 | A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment…(DUETTE) | Phase 2 | withdrawn | Jan 23, 2020 | AstraZeneca | Sponsor made the decision to terminate the DUETTE study based on the interim analysis of the… | Efficacy / futility |
| NCT03134638 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | May 1, 2017 | Syros Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT01334047 | Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | Phase 1 / Phase 2 | terminated | Apr 12, 2011 | Steinar Aamdal | The study needed to be terminated due to new knowledge about cancer vaccines. A new protocol with… | Other (stated, no rule matched) |
| NCT03146663 | NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer | Phase 2 | terminated | May 10, 2017 | NuCana plc | Despite promising efficacy and a good tolerability profile in Part I, it was decided not to… | Efficacy / futility |
| NCT03622931 | Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy…(TRACEII) | Phase 2 | terminated | Aug 9, 2018 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | due to lack of recruitment | Enrollment / accrual |
| NCT03162562 | The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in… | Phase 1 | terminated | May 22, 2017 | CanariaBio Inc. | Sponsor Decision to discontinue long-term follow-up | Sponsor / business decision |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | Phase 1 | terminated | Oct 27, 2016 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal… | Phase 1 / Phase 2 | withdrawn | Apr 1, 2010 | Imperial College London | Failure to recruit. | Enrollment / accrual |
| NCT01511055 | Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific… | Phase 2 | terminated | Jan 18, 2012 | Mayo Clinic | Accrual temporarily suspended, followed by study closure due to technical problems with… | Enrollment / accrual |
| NCT03292172 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and… | Phase 1 | terminated | Sep 25, 2017 | Hoffmann-La Roche | Portfolio prioritization | Sponsor / business decision |
| NCT03203993 | China Ovarian Cancer BRCA Testing Study(CRONUS) | — | terminated | Jun 29, 2017 | AstraZeneca | Failure to obtain HGR approval. | Other (stated, no rule matched) |
| NCT02476955 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | Phase 1 | terminated | Jun 22, 2015 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | not stated | Not stated |
| NCT01690468 | PTX-200 and Carboplatin in Ovarian Cancer | Phase 1 / Phase 2 | terminated | Sep 21, 2012 | Prescient Therapeutics, Ltd. | Enrollment stopped prior to Phase 1b, change in strategic focus | Enrollment / accrual |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT01535157 | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | Phase 1 / Phase 2 | terminated | Feb 17, 2012 | South Plains Oncology Consortium | drug combination not providing any efficacy. Will use this data in opening new trial | Efficacy / futility |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in… | Phase 1 | terminated | Jan 27, 2015 | Famewave Ltd. | not stated | Not stated |
| NCT02326844 | BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2… | Phase 2 | terminated | Dec 30, 2014 | National Cancer Institute (NCI) | Study was closed by the Cancer Therapy Evaluation Program (CTEP) | Other (stated, no rule matched) |
| NCT03587129 | Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer | Phase 2 | terminated | Jul 16, 2018 | First Affiliated Hospital of Harbin Medical University | No patient enter this study. | Other (stated, no rule matched) |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN… | Phase 3 | terminated | Mar 24, 2016 | Pfizer | The study was terminated based on the results of a planned interim analysis that showed futility of… | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 28, 2022source: clinicaltrials